-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OiPtbeYbApvoPgh/czspnd8Z9PJzJFCFyec1zoAxSfUldI8mGa2L4LEQJcx+GR8P
 YhFlO78C6sBWxBDz7Gb9kg==

<SEC-DOCUMENT>0001130319-06-000261.txt : 20060404
<SEC-HEADER>0001130319-06-000261.hdr.sgml : 20060404
<ACCEPTANCE-DATETIME>20060404123020
ACCESSION NUMBER:		0001130319-06-000261
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060404
FILED AS OF DATE:		20060404
DATE AS OF CHANGE:		20060404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		06736555

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o30941e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of April 2006

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date: April&nbsp;4, 2006</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "Press Release" -->

<P>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="top">
        <TD width="70%"><IMG src="o30941o3094100.gif" alt="Oncolytics Biotech Logo"></TD>
        <TD width="30%">210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
</TABLE>




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Oncolytics Biotech Inc.&#146;s Research Collaborators Present Interim Phase I<BR>
Combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>/Radiation Clinical Trial Data at AACR Conference</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY,
AB, &#151; April&nbsp;4, 2006</B> &#151; Oncolytics Biotech Inc. (&#147;Oncolytics&#148;) (TSX:ONC, NASDAQ:ONCY)
announced today that interim results of its Phase I combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>/radiation clinical trial
will be presented this morning at the American Association for Cancer Research (AACR)&nbsp;annual
meeting in Washington, D.C. The interim results indicated that the combination of intratumoural
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and radiation was well tolerated and that both local clinical responses and early
indications of systemic effects were observed. The presentation is entitled &#147;Phase I trial of
intratumoural administration of reovirus type 3 (Reolysin) in combination with radiation in patients
with advanced malignancies.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Indications of activity when combining REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> with what is generally considered to be a
palliative dose of radiation are certainly encouraging,&#148; said Dr.&nbsp;Brad Thompson, President and CEO
of Oncolytics. &#147;On the strength of this data, we are currently designing a Phase II combination
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>/radiation trial, at this radiation dosage, for inclusion in our overall Phase II clinical
program. That trial is expected to begin following the completion of the ongoing Phase I trial.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Phase I open label study is evaluating the feasibility, safety and anti-tumour effects of
intratumoural administration of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> in combination with localized radiation therapy in
patients with advanced cancers, using two different radiation dosages and schedules. The primary
objective of the study is to determine the maximum tolerated dose and dose limiting toxicities, if
any, and the safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> when administered intratumourally to patients receiving
radiation treatment. The secondary objective is to examine any evidence of anti-tumour activity.
Patients with advanced or metastatic solid tumours that are refractory to standard therapy, or for
which no curative standard therapy exists, are eligible. The patients will have a target lesion
that has not previously been treated with radiation but for which palliative radiation treatment is
indicated. The treatment consists of a constant amount of radiation, in this case 20 Grays,
administered in five fractions on consecutive days, and two intratumoural injections of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
on days two and four at the following dose escalation levels &#151; 10<SUP style="font-size: 85%; vertical-align: text-top">8</SUP>, 10<SUP style="font-size: 85%; vertical-align: text-top">9</SUP> and
10<SUP style="font-size: 85%; vertical-align: text-top">10</SUP> TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50</SUB>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Preliminary observations in the first seven patients show that the combination of intratumoural
REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and radiation has been well-tolerated. Most toxicities have been mild, generally grade 1
and 2, and include fever, sweating and skin erythema. One patient in the second cohort developed
grade 3 fatigue and grade 2 flu-like symptoms and could not receive the second REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> injection.
There has been no evidence that the REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> injections exacerbated the acute reactions expected
from the radiation. There was also no evidence of viral shedding in the blood, urine, stool or
sputum on day eight post-REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> injection.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Interim analysis has shown evidence of local responses and an indication of systemic effects.
Amongst the first five patients that completed treatment, three patients had partial tumour
responses. There was one case of progressive disease at one month, one case of stable disease at
one month, two cases of partial responses at one, two and three months and one case of stable
disease at one and two months, which became a pathological partial response at three months. CT
scans from the treated lymph node tumour in the first patient in the trial clearly show the partial
response, which has now lasted for over eight months. A metastatic tumour in this patient that was
outside the radiation field also showed a partial response.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Oncolytics will host a webcast at 12:00&nbsp;p.m. ET today, April&nbsp;4, 2006, to provide a clinical trial
update specifically focusing on the interim Phase I combination REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>/radiation clinical trial
results being presented in an oral presentation at the AACR Annual Meeting. The presentation will
be available on the Oncolytics website later today.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The live audio webcast will be available at:<BR>
<U>http://w.on24.com/r.htm?e=21624&#038;s=1&#038;k=60E516ABE1419DCAB6502DB7A33029D1</U> or through
<U>www.oncolyticsbiotech.com</U>. Please connect to the link at least 15 minutes prior to the webcast to
ensure adequate time for any software download that may be needed. A replay of the webcast will be
available at <U>www.oncolyticsbiotech.com</U> and will also be available by telephone through April&nbsp;13,
2006. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation
number 21182106.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I and
Phase I/II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human reovirus, alone
and in combination with radiation. For further information about Oncolytics, please visit
<U>www.oncolyticsbiotech.com</U>.
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
implication of the materials presented at this meeting with respect to REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, the Company&#146;s
expectations related to the results of trials investigating delivery of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, and the
Company&#146;s belief as to the potential of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a cancer therapeutic, involve known and
unknown risks and uncertainties, which could cause the Company&#146;s actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects,
the efficacy of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> as a cancer treatment, the schedule, success and timely completion of
clinical studies and trials, the Company&#146;s ability to successfully commercialize REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
uncertainties related to the research and development of pharmaceuticals and uncertainties related
to the regulatory process. Investors should consult the Company&#146;s quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not undertake to update these
forward-looking statements.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="58%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Oncolytics Biotech Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Cathy Ward</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">210, 1167 Kensington Cr NW</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Toronto Street</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Calgary, Alberta T2N 1X7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toronto, Ontario M5C 2B8</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Tel: 403.670.7377</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 416.815.0700 ext. 226</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Fax: 403.283.0858</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 416.815.0080</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><U>cathy.ward@oncolytics.ca</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><U>www.oncolyticsbiotech.com</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">The Investor Relations Group</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RenMark Financial Communications</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Damian McIntosh</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">John Boidman</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">11 Stone Street, 3rd Floor</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2080 Rene Levesque Blvd. W.</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">New York, NY 10004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montreal, PQ H3H&nbsp;1R6</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 514.939.3989</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 514.939.3717</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top"><U>dmcintosh@investorrelationsgroup.com</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>jboidman@renmarkfinancial.com</U></TD>
</TR>
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;
<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>

</DIV>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o30941o3094100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o30941o3094100.gif
M1TE&.#EA\@`W`/<``/______S/__F?__9O__,___`/_,___,S/_,F?_,9O_,
M,__,`/^9__^9S/^9F?^99O^9,_^9`/]F__]FS/]FF?]F9O]F,_]F`/\S__\S
MS/\SF?\S9O\S,_\S`/\`__\`S/\`F?\`9O\`,_\``,S__\S_S,S_F<S_9LS_
M,\S_`,S,_\S,S,S,F<S,9LS,,\S,`,R9_\R9S,R9F<R99LR9,\R9`,QF_\QF
MS,QFF<QF9LQF,\QF`,PS_\PSS,PSF<PS9LPS,\PS`,P`_\P`S,P`F<P`9LP`
M,\P``)G__YG_S)G_F9G_9IG_,YG_`)G,_YG,S)G,F9G,9IG,,YG,`)F9_YF9
MS)F9F9F99IF9,YF9`)EF_YEFS)EFF9EF9IEF,YEF`)DS_YDSS)DSF9DS9IDS
M,YDS`)D`_YD`S)D`F9D`9ID`,YD``&;__V;_S&;_F6;_9F;_,V;_`&;,_V;,
MS&;,F6;,9F;,,V;,`&:9_V:9S&:9F6:99F:9,V:9`&9F_V9FS&9FF69F9F9F
M,V9F`&8S_V8SS&8SF68S9F8S,V8S`&8`_V8`S&8`F68`9F8`,V8``#/__S/_
MS#/_F3/_9C/_,S/_`#/,_S/,S#/,F3/,9C/,,S/,`#.9_S.9S#.9F3.99C.9
M,S.9`#-F_S-FS#-FF3-F9C-F,S-F`#,S_S,SS#,SF3,S9C,S,S,S`#,`_S,`
MS#,`F3,`9C,`,S,```#__P#_S`#_F0#_9@#_,P#_``#,_P#,S`#,F0#,9@#,
M,P#,``"9_P"9S`"9F0"99@"9,P"9``!F_P!FS`!FF0!F9@!F,P!F```S_P`S
MS``SF0`S9@`S,P`S````_P``S```F0``9@``,P``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````#R`#<```C_``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6&*S)FO,BQH\>/($.*I&B%2R!6UZ#-NG8-):M`
M5E:,G$FSILV;%U><O!:-):M9UEK):GEM:,N8.),J7<J4XXJ?UJX)5<FJ5*"K
MK++V1#DTD,RF8,.*9>I2ZDLK"E=88=6*Z,NQ<./*O;C6+5*':HG.8O5UKM^_
M@`4&*AJ-%=J).EE!.QJXL>.F.HEZS8D(Y;7#CS-K%CDX*^:+)#I?WDRZ=$71
MGSNB-LVZM4(K1:_U!0E;5K39KG.;7A'-=FJ0@7JSTDW<-"O;@6RBC,:EN//'
M=5D9L!F#55#<S[/#13D+^\A`0)-K_Q\_%C:TX3A70&M+OCW8K+-^T^PLWKU]
MFT];+ETQ%/W]_R/5M@=9O0%H8$@[R5=3(+X=Z"!'+GE7DX`(77450E5<)6%!
M5IR4U5D;"J26AUG!%"(`.L'$4(<:)L3B9RQ:*..,V*6H($$C?HB(B@DE]F&)
M=QWD$F2S1',(0L<)=U`7*-V(HF4E[E24@FNY]%(@B*C$&$)UU:=09WP=-)@L
M_@F4E5MHEO5;EU]"N6,I9X;)(906PJ>2EP.MT%*92J7$YT"L]+:507IL*29+
MDQ6TD9@1&O145][!EI5#@^V%6V>F,-3H0I+^*:)+7>"V*(<^U:@60OQ=@V=2
M/WD*P'&7;?\JD!4K*>C2JISVIU`I;>%J15</!;*8G*^R=*2F0YT(P*^J'O24
M2D]`Q."D$?$F"ZXW68:D5``P6%A?YG5QT%I[2812*T[6=IM!5O26:;"V\179
M6PT%VMV*[AXZBQ[56AF3LB(6B:U-K5CCJF+7"&:-I;,V>>AYU<ZR6(C\];:F
M;<?"N^=*`QL$E;*_&GD040`;Y.$U*[%RR+\]+EP*6&8A"50`@D5CL$RUR3=F
MQ\ZB;`T+"I5`V)KY1K23=3P7I-B]G!:-8ZD5=7AF3RT=(N&03/%G,)(J]<5%
M6WQ5T9;.\59[WF@]VA8?NQA/M),@$?TDVXIM>XQ2#!ZIM5S"0K;_5/)'[<XR
M8-_0S%8;*RQ8$XU\UA)+Z9ZO]0;-`>P6]:[1+:T2-S2R@&RYOI=W]&@KWNWT
MMT>!%&SK+$P/U&Y+M7*YE9-]H^WHN8",&VC&$.TQ%-P0R0WR[@>5<,AB5N<=
MJ#61HLSO4M:U,AWAV-7%^8WDGF=%3-N79`KC.\'T;XZ&DDIF]^@'>1`7O;T<
M?-<K?EYAH-=NK];V+1+D4O=JC=B?@GJB5E)4@#)H).1,D9(;[:2V$K>88F4N
M.HG$)N@N+FRH+E1CB0;GEA`]%(EW]9+8\)K5HT"8HBPN.42B1(25#4+)%"OL
M6^MN<@7D*$0%"R%!M4;E$!)H9`4X?!"._S2"EXRPK"&_@AA.`J"XS@GQB161
M"O-P4IND0?&*)@N*JT#R%)2<#HM8W)]R$`7&,CJD+AP<"2"$LL4\H4@D/.S1
M&P$FDY+%T5D$T:'H&/)%$?7Q4"B9B14*MCA-&>8D/`L$"&\G/L.DI4/7XM'\
MKK*]A5"R0R%*XPPI\I00P48\:UF(C3K4$5@YKB.#7)@5S\*BA7`A=(Y*(P!L
MEQ!9SJ]["Z%7O<1G!6C0#B-\<Y%A^!+*A!B`EJ)CB]\`=XV@6/%57M%;B/:P
M2!PY4D2R@`)#2,<0#=VQ(!=RR&4TLDG$G))#LE@6*P#1QA)<DXMG0B9B1/-,
M:'8OANSBF4ZZMY*'7[X*9+QTT@JN`(CN!1%)?3FG1)["*?2L0!#Z#.AK%+HM
ME.`3(FM16SW-R%&3$4557^RB%/W9T9(Z2F*R*-@[2\B=/?W1I"8USUY\PLKM
MF80M05G8>5X*TYY&IX!`*5A;;";%5I0";SU-:D5&I)*<`J4W>S&14J?JE!]J
8I`14S:I6M\K5KGKUJV`-JUC'NM6````[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
